Veru Inc is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of diseases, particularly in the areas of oncology and urology
The company is engaged in the research and development of novel drug candidates aimed at addressing unmet medical needs, with a strong emphasis on advancing therapies for prostate cancer and other challenging health conditions. Veru is also involved in the production of specialty pharmaceutical products, showcasing its commitment to improving patient outcomes through scientific innovation and rigorous clinical trials.
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Companies Reporting Before The Bell • Ares Management (NYSEARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million.
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQRARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Shares of bluebird bio, Inc. (NASDAQBLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.
